Hepatitis B-related Acute-on-chronic Liver Failure Induced by Hepatotropic Viral Insult is Associated with Worse Prognosis Than That Induced by Non-virus Insult
Overview
Authors
Affiliations
Background: The manifestations and prognoses of acute-on-chronic liver failure (ACLF) with different precipitating events remain heterogeneous. We aimed to investigate the characteristics and prognosis of patients with hepatotropic viral insult (HVI)-induced hepatitis B-related ACLF (HBV-ACLF).
Methods: 452 patients with confirmed diagnosis of ACLF were screened in three medical centers in China, and 203 HBV-ACLF patients with definite acute precipitating events were retrospectively analyzed. According to the precipitating events, HBV-ACLF patients induced by HBV reactivation and super-infection with HAV were classified as the hepatotropic viral insult group and those induced by other factors, as the non-virus insult (NVI) group. The clinical characteristics, predictive scoring model, and prognosis of the two groups were compared.
Results: Hepatitis B virus reactivation accounted for the largest proportion (39.9%) among all precipitating events. Exacerbation time frame of the HVI group was significantly longer than that of the NVI group (20 days vs. 10 days, P < 0.001). Comparison of intergroup prognosis showed that there was no significant difference in the 28 day mortality (20.9 vs. 13.7%, P = 0.125), while the 90 day and 1 year mortality in the HVI group were higher than those in the NVI group (36.3 vs. 24.4%, P = 0.014; 39.5% vs. 27.5%, P = 0.020, respectively). In the HVI group, the lactic acid-free APASL-ACLF Research Consortium (AARC) had better predictive value for 90 day mortality (0.741).
Conclusions: The 90 day and 1 year survival rate was lower in HBV-ACLF patients induced by HVI than by NVI. The lactate-free AARC score was a better predictor of short- and long-term prognosis in patients with HVI-induced HBV-ACLF.
Progress on clinical prognosis assessment in liver failure.
Cai X, Chong Y, Gan W, Li X Liver Res. 2025; 7(2):101-107.
PMID: 39958953 PMC: 11791918. DOI: 10.1016/j.livres.2023.05.004.
Determinants of outcomes in patients with hepatitis B virus-decompensated cirrhosis.
Huang Y, Wang J, Chen C, Lee S, Chang C, Liao S Sci Rep. 2025; 15(1):562.
PMID: 39747298 PMC: 11696113. DOI: 10.1038/s41598-024-84413-0.
Lyu C, Han J, Kang N, Zeng D, Davgadorj C, Ge L Gastroenterol Res Pract. 2024; 2024:5512889.
PMID: 39723429 PMC: 11669432. DOI: 10.1155/grp/5512889.
Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B.
Sun T, Chi H, Wang J, Zheng Y, Zhu H, Zhao J BMC Infect Dis. 2024; 24(1):1428.
PMID: 39695950 PMC: 11654415. DOI: 10.1186/s12879-024-10324-0.
Prevalence of Hepatitis B Virus Markers among the Women with Breast Cancer.
Fakheri Sueini V, Parsa Nahad M, Talaeizadeh A, Moradi M, Alborzi A, Pirmoradi R Asian Pac J Cancer Prev. 2024; 25(2):547-553.
PMID: 38415541 PMC: 11077112. DOI: 10.31557/APJCP.2024.25.2.547.